Novo Nordisk is committed to preventing the misuse of semaglutide.
filed by a Danish company several lawsuits in the US Block the advertising and sale of counterfeit semaglutide products to certain medical spas, weight loss or wellness clinics and dispensing pharmacies, some of which misuse Novo Nordisk trademarks.
The world’s largest diabetes care company considers that compounded products “do not have equal assurances of safety, quality or efficacy,” and believes that unlawful marketing and sales practices by third parties can lead to “consumer confusion and It raised a high risk of fraud and potential security concerns.” The company’s products have been approved by the Food and Drug Administration (FDA).
Target Company: Novo Nordisk
Novo Nordisk markets this weight loss drug under three different brands. Ozempic Injection and Libersus Tablets for type 2 diabetes and Wegoby Injection for chronic weight management.
The company is the only company in the United States to have Food and Drug Administration (FDA) approval for a product containing semaglutide. “All three drugs are only available by prescription and have no approved generic versions.” The FDA said in May that.
Companies like WeightWatchers signed a valid transaction In order to give customers access to these products, other companies stock counterfeit products.
The list of companies that Novo Nordisk has sued to date is not exhaustive
Companies accused of unfairly misusing Wegovy’s trademark to market their own medicines in the Novo Nordisk lawsuit include:
Fake Ozempic is rampant due to drug shortage
Novo Nordisk struggling to meet demand for medicine. In May, the FDA regulated both Ozempic and Wegovy. medicine shortage list.Under these circumstances, it is is allowedHowever, state regulators are concerned about drugs manufactured with semaglutide sodium salt. cheaper improved version This compound is suitable for scientific research, but not for human use.At least four states already crackdown on counterfeit goods.
Alarm bells have already been rung over reduced safety Substitute for aftermarket products. On June 16, Novo Nordisk worked with the FDA to warned the public A counterfeit Ozempic pen has been found in the United States. Counterfeit products sold in pharmacies appeared to contain a type of diabetes drug that worked differently than Ozempic, causing side effects.
On the other side of the world, in Australia, a few online scammers sells ducks. Medicines often do not arrive.
Quote: Semaglutide compound problem
“Patients should be aware that some products marketed as ‘semaglutide’ do not contain the same active ingredient as FDA-approved semaglutide products and may be salt formulations.” . Products containing these salts, such as semaglutide sodium and semaglutide acetate, have not been proven safe and effective. “ —U.S. FDA In a May 31 statement
One of the big numbers is the growing global weight loss drug market.
15%: A 2021 study published in the New England Journal of Medicine found that people with a BMI of 30 or higher who took semaglutide, the active ingredient in Wegobee and Ozempic, lost weight each week on average after 17 months. .
$200 billion: Barclays forecasts how large the global weight loss therapy market will be over the next decade. Novo Nordisk is a prime candidate to benefit from this wave given its first-mover advantage and dominance in this space.
$364.5 billion: Novo Nordisk ranks second in Europe by market capitalization as of June 20
$30: Groupon Offers 7-Week ‘Semaglutide Weight Management Program’ Presented by Cosmetic Laser Professionals Med Spa in Ekzotika, Miami
Novo Nordisk Semaglutide Resource Bank
Novo Nordisk launched semaglutide.com Serving as a trusted resource hub for US audiences, including patients, healthcare providers, retailers…
🔈 …disseminate information about the responsible use of Novo Nordisk’s FDA-approved semaglutide products.
🔍 …highlights the difference between the company’s vetted product and other drugs labeled as “semaglutide.”
💉 …to provide patrons with the tools to spot counterfeit injections. For example, the genuine Novo Nordisk Ozempic Pens do not stretch or lengthen when dosed and are available in three variations (0.25/0.5 mg, 1 mg and 2 mg pens). A very specific dose dial window is provided. The minimum dose version comes with 6 needles and the other 2 come with 4 needles. For the Wegovy pen, there is no option to set the dose, it does not lengthen or lengthen, and it is only available in 5 configurations: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg. . .
One More: Novo Nordisk Placebo Reports
1-800-727-6500: The Novo Nordisk Customer Care Helpline is available Monday through Friday from 8:30 a.m. to 6:00 p.m. Eastern Standard Time to report suspected counterfeit semaglutide products or counterfeit Novo Nordisk products.
1-800-551-3989: FDA Office of Criminal Investigation (OCI) helpline for reporting websites that sell counterfeit or falsified medicines.
Related article
🏥 Insurance coverage for Ozempic shows the complexity of obesity treatment
💼 WeightWatchers opens the door to the difficult business of weight loss drugs
